quercetin
Quercetin is a unique bioflavonoid that has been extensively studied by researchers over the past 30 years. Quercetin, the most abundant of the flavonoids (the name comes from the Latin –quercetum, meaning oak forest, quercus oak) consists of 3 rings and 5 hydroxyl groups. Quercetin is a member of the class of flavonoids called flavonoles and forms the backbone for many other flavonoids including the citrus flavonoids like rutin, hesperidins, Naringenin and tangeritin. It is widely distributed in the plant kingdom in rinds and barks. The best described property of Quercetin is its ability to act as antioxidant. Quercetin seems to be the most powerful flavonoids for protecting the body against reactive oxygen species, produced during the normal oxygen metabolism or are induced by exogenous damage [9, 10]. One of the most important mechanisms and the sequence of events by which free radicals interfere with the cellular functions seem to be the lipid peroxidation leading eventually the cell death. To protect this cellular death to happen from reactive oxygen species, living organisms have developed antioxidant line of defense systems [11]. These include enzymatic and non-enzymatic antioxidants that keep in check ROS/RNS level and repair oxidative cellular damage. The major enzymes, constituting the first line of defence, directly involved in the neutralization of ROS/RNS are: superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) The second line of defence is represented by radical scavenging antioxidants such as vitamin C, vitamin A and plant phytochemicals including quercetin that inhibit the oxidation chain initiation and prevent chain propagation. This may also include the termination of a chain by the reaction of two radicals. The repair and de novo enzymes act as the third line of defence by repairing damage and reconstituting membranes. These include lipases, proteases, DNA repair enzymes and transferases. Quercetin is a specific quinone reductase 2 (QR2) inhibitor, an enzyme (along with the human QR1 homolog) which catalyzes metabolism of toxic quinolines. Inhibition of QR2 in plasmodium may potentially cause lethal oxidative stress. The inhibition of antioxidant activity in plasmodium may contribute to killing the malaria causing parasites. — NCATS
Clinical trial activity
92 trials · 106 clinical orgs · 0 marketing orgs
Earliest trial started Aug 1, 1996 (NCT00003365)
Timeline
Indications
Approved for
Studied for
- Aging · Phase 2
- Aging, Premature · Phase 2
- Altitude Sickness · Phase 3
- Alzheimer Disease · Phase 2
- Asthma · Phase 2
- Autism Spectrum Disorder · Phase 2
- Breast Neoplasms · Early Phase 1
- Bronchitis · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Cardiovascular Diseases · Phase 2
- Cesarean Section · Phase 3
- Cognitive Dysfunction · Phase 2
- Coronary Artery Disease · Phase 3
- COVID-19 · Phase 4
- Cystic Fibrosis · Phase 2
- Depressive Disorder, Treatment-Resistant · Phase 2
- Diabetes Mellitus · Phase 2
- Diabetes Mellitus, Type 2 · Phase 2
- Diabetic Neuropathies · Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 1/Phase 2
- Emphysema · Phase 2
- Fanconi Anemia · Phase 2
- Fibrosis · Phase 1/Phase 2
- Flushing · Phase 4
- Frailty · Phase 2
- Gastroesophageal Reflux · Phase 1
- Geriatrics · Phase 2
- Glioma · Early Phase 1
- Healthy Lifestyle · Early Phase 1
- Healthy Volunteers · Phase 2
- Hepatitis C, Chronic · Phase 1
- HIV · Phase 2
- Hyperuricemia · Phase 4
- Idiopathic Pulmonary Fibrosis · Phase 1
- Immune System Diseases · Phase 2
- Inflammation · Phase 1
- Lichen Planus · Phase 1
- Liver Cirrhosis · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 2
- Macular Degeneration · Phase 2
- Menopause · Phase 4
- Motor Activity · Phase 2
- Mouth Neoplasms · Phase 2
- Multiple Myeloma · Phase 2
- Neoplasms · Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 1/Phase 2
- Obesity · Phase 2
- Osteoporosis · Phase 2
- Pain · Early Phase 1
- Periodontal Pocket · Phase 2
- Peripheral Nerve Injuries · Early Phase 1
- Phytotherapy · Phase 1
- Polycystic Ovary Syndrome · Phase 2
- Postoperative Pain · Phase 3
- Prostatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 1/Phase 2
- Psoriasis · Phase 1
- Pulmonary Disease, Chronic Obstructive · Phase 2
- Renal Insufficiency, Chronic · Phase 2
- Schizophrenia · Phase 2
- Sedentary Behavior · Phase 2
- Severe Acute Respiratory Syndrome · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stroke · Early Phase 1
- Thromboembolism · Phase 3
- Triple Negative Breast Neoplasms · Phase 2
Mechanism of action
- Unspecified targetAntioxidant
antioxidant
Chemistry & pharmacology
SMILES
O.O.OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C3=CC=C(O)C(O)=C3- Mol. weight
- 338.2663 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaQuercetin ↗
- NCATS53B03V78A6 ↗
- ChEMBLCHEMBL50 ↗
- ChEMBLCHEMBL2103922 ↗
Also known as
- 3,3',4',5,7-pentabenzyloxyflavone
- 3,5,7,3',4'-pentahydroxyflavone
- 3,5,7,3',4'-pentahydroxyflavone
- benzquercin
- benzquercin
- benzquercin
- benzquercin
- benzquercine
- parietrope
- potassium quercetin phosphate
- qr-333
- quercetin
- quercetin
- quercetin
- quercetin
- quercetin
- quercetin
- quercetin
- quercetin-3'-o-phosphate
- quercetine
- quercetin pentabenzyl ether
- quercetol
- quertine
- xanthaurine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07270120 | Phase 1 | Jan 15, 2026 | Ohio State University |
| NCT07144293 | Phase 2 | Oct 15, 2025 | National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Aging (NIA) |
| NCT07182526 | Phase 2 | Sep 20, 2025 | Al-Mustansiriyah University |
| NCT07025226 | Early Phase 1 (Phase 1) | Aug 12, 2025 | Mayo Clinic |
| NCT07000734 | Phase 2 | Jul 31, 2025 | Washington University in St. Louis |
| NCT06974058 | N/A | Jul 22, 2025 | Liaquat University of Medical & Health Sciences |
| NCT06940297 | Phase 2 | Jun 23, 2025 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT06796374 | N/A | Feb 1, 2025 | University of Greifswald |
| NCT06683534 | N/A | Jan 31, 2025 | Medical College of Wisconsin |
| NCT06615752 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2024 | Charles Drew University, National Institutes of Health (NIH) |
| NCT06650891 | Phase 3 | Oct 31, 2024 | Future University in Egypt |
| NCT06982248 | Phase 2 | Aug 15, 2024 | Mansoura University |
| NCT06470061 | Phase 2 | Jul 31, 2024 | Northwestern University, Zaparackas and Knepper LTD |
| NCT06355037 | Phase 2 | May 20, 2024 | Fudan University |
| NCT06230861 | N/A | Mar 1, 2024 | University of Central Lancashire |
| NCT06775392 | Phase 1 | Jan 4, 2024 | Krishnadevaraya College of Dental Sciences & Hospital |
| NCT05928546 | Phase 1 | Oct 20, 2023 | Assiut University |
| NCT06591767 | N/A | Oct 1, 2023 | Liaquat University of Medical & Health Sciences, University of Urbino "Carlo Bo" |
| NCT06003270 | Phase 2 | Sep 30, 2023 | National Center for Complementary and Integrative Health (NCCIH), National Institutes of Health (NIH), Quercegen Pharmaceuticals, Temple University |
| NCT06018467 | Phase 2 | Sep 6, 2023 | Novo Nordisk, University of Southern Denmark |